Skip to main content

Bio-Techne Corp Value Stock - Dividend - Research Selection

Bio-techne

ISIN: US09073M1045 , WKN: A12ENG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

2025-12-16
Despite Bio-Techne’s weak performance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Here’s Why BioTechne (TECH) Traded Lower in Q3

2025-12-11
Mairs & Power, an investment advisor, released the third-quarter 2025 investor letter for the “Mairs & Power Balanced Fund.” A copy of the letter can be downloaded here. As we move into 2025, the market’s concentration persists, with a few dominant mega-cap stocks tied to artificial intelligence (AI) driving most of the favorable outcomes. The […]

Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology

2025-12-11
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced a strategic collaboration between one of its spatial biology brands, Lunaphore, and the Wyss Center for Bio and Neuroengineering (Wyss Geneva) to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens. The project will enable high-resolution multiomic analysis within intact 3D samples.

Does Bio-Techne’s Recent Weakness Offer an Opportunity After Its Cell and Gene Therapy Push?

2025-12-09
Wondering if Bio-Techne at around $60 a share is a bargain in disguise or a value trap? This breakdown will walk you through what the numbers are really saying about the stock. Despite being down about 21.7% over the last year and 15.7% year to date, the stock has shown some near term resilience with a 5.0% gain over the past month, even after slipping 5.4% in the last week. Recent headlines have focused on Bio-Techne expanding its portfolio of life science tools and strengthening...

Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis

2025-12-09
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the expanded launch and first shipment of its next-generation Leo™ System, powered by Simple Western™ Technology.

Bio-Techne Corporation (TECH) Presents at 53rd Annual Nasdaq Investor Conference Transcript

2025-12-09
Bio-Techne Corporation (TECH) 53rd Annual Nasdaq Investor Conference December 9, 2025 4:30 AM ESTCompany ParticipantsKim Kelderman - CEO, President &...

Bio-Techne Corporation (TECH): A Bull Case Theory

2025-12-04
We came across a bullish thesis on Bio-Techne Corporation on Valueinvestorsclub.com by rab. In this article, we will summarize the bulls’ thesis on TECH. Bio-Techne Corporation’s share was trading at $64.63 as of November 26th. TECH’s trailing and forward P/E were 134.39 and 33.22 respectively, according to Yahoo Finance. Bio-Techne, founded in 1976 and reshaped through a series of […]

Bio-Techne Corporation (TECH) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

2025-12-03
Bio-Techne Corporation (TECH) Citi Annual Global Healthcare Conference 2025 December 3, 2025 3:15 PM ESTCompany ParticipantsJames Hippel - Executive VP of...

Evolve Announces Estimated Annual Distributions for Certain Evolve Funds

2025-12-02
Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - Evolve Funds Group Inc. ("Evolve") announces the estimated special year end cash income and non-cash notional reinvested income and capital gains distribution per unit (the "Distributions") for certain Funds (the "Evolve Funds") for the 2025 tax year.These estimates are for the annual cash income and non-cash capital gains and income distributions. Non-cash capital gains and income distributions are typically reinvested in additional units.

Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript

2025-12-02
Bio-Techne Corporation (TECH) Evercore 8th Annual Healthcare Conference December 2, 2025 8:20 AM ESTCompany ParticipantsJames Hippel - Executive VP of...